India, June 17 -- Pune-based Serum Institute of India (SII), part of Cyrus Poonawalla Group, the world's largest vaccine manufacturer, and the not-for-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) have signed a Memorandum of Understanding (MoU) to accelerate the clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs).
Through this collaboration, both SII and DNDi will develop a work plan to implement R&D, additional Phase III clinical trials, and access activities, along with a joint strategy to raise necessary funds and resources.
Additionally, a joint project team will be formed to advance clinical trials...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.